NICE approves immunotherapy combination for advanced melanoma.
London.
Jacqui
J
Wise
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use; D017277:Drug Approval; D016527:Drug Costs; D006801:Humans; D007167:Immunotherapy / Q000191:economics / Q000379:methods; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy* / Q000191:economics; D000077594:Nivolumab; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000191:economics; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D000074324:Ipilimumab; D000077594:Nivolumab